Clinical Roundup Degradation of HER2, EGFR may overcome drug resistance in HER2-positive breast cancers May 31, 2024Vol.50 No.22
Clinical Roundup PKMYT1 is a potential target for treatment-resistant ER+ breast cancers May 31, 2024Vol.50 No.22
Clinical Roundup Keytruda improves OS for high-risk early-stage TNBC in phase III trial May 31, 2024Vol.50 No.22
Clinical Roundup Kisqali reduces risk of cancer recurrence for HR+/HER2- early breast cancer in phase III trial May 31, 2024Vol.50 No.22
Drugs & Targets Cartography, Gilead collaborate to develop therapies for breast and lung cancers May 31, 2024Vol.50 No.22
Trials & Tribulations Are we focused on the wrong risk type in genetic screening?Breast cancer screening study shows new paths to population screening May 24, 2024Vol.50 No.21By Cassie Hajek
Clinical Roundup Orserdu combinations show favorable safety profiles for ER+, HER2- metastatic breast cancer in phase Ib/II trials May 24, 2024Vol.50 No.21
Clinical Roundup Vepdegestrant + Ibrance continue to show clinical benefit for ER+/HER2- breast cancer in phase Ib trial May 24, 2024Vol.50 No.21
Clinical Roundup UCLA study: Combination of breast cancer and chemo may speed physical decline in older adults May 17, 2024Vol.50 No.20
